Allergy Clinical Trial Services Global Market Report 2026

The allergy clinical trial services market size has grown strongly in recent years. It will grow from $1.15 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of allergic diseases, rising investment in clinical research, adoption of structured study protocols, expansion of laboratory testing infrastructure, growth of pharmaceutical and biotechnology companies.

The allergy clinical trial services market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing focus on precision medicine approaches, increasing integration of ai-driven analytics, rising demand for remote monitoring and decentralized trials, expansion of phase ii and iii allergy studies, growing emphasis on regulatory compliance and data management. Major trends in the forecast period include increasing adoption of remote clinical monitoring services, rising demand for patient recruitment and retention solutions, growing integration of electronic data capture (edc) systems, expansion of bioanalytical and laboratory testing capabilities, rising focus on regulatory compliance and medical writing services.

The growing prevalence of allergic diseases is projected to stimulate the expansion of the allergy clinical trial services market in the years ahead. Allergic diseases are hypersensitivity conditions mediated by the immune system, including seasonal allergic rhinitis, eczema, and food allergies. The occurrence of these conditions is increasing, primarily due to heightened exposure to environmental allergens such as pollen, dust, and air pollutants, which are strongly linked to increased immune system hypersensitivity among susceptible individuals. Allergy clinical trial services facilitate the management and treatment of allergic diseases by supporting the development, testing, and assessment of new therapies and interventions, thereby assisting healthcare providers in identifying effective solutions and enhancing patient outcomes. For instance, according to the 2024 National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention, about 29.5% of children in the United States had been diagnosed with a seasonal allergy, eczema, or a food allergy, compared to 20.6% in the preceding survey year. Therefore, the rising incidence of allergic diseases is propelling the growth of the allergy clinical trial services market.

Key companies operating in the allergy clinical trial services market are concentrating on conducting clinical trials to develop innovative products such as novel anti-inflammatory drugs to enhance symptom management and decrease disease severity in allergy patients. Novel anti-inflammatory drugs are newly developed therapies formulated to target specific immune pathways responsible for inflammation, thereby reducing allergic reactions, alleviating symptoms, and preventing disease flare-ups more efficiently than conventional treatments. For example, in December 2023, Innovaderm Research, a Canada-based clinical research organization, underscored its role as a principal collaborator in the clinical and study development of a recently published Phase 1 atopic dermatitis study. The study assessed the safety, tolerability, and preliminary efficacy of an investigational therapy in patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin disorder frequently associated with allergic responses. Innovaderm contributed to protocol design, regulatory planning, site identification, patient enrollment, and comprehensive operational oversight, ensuring compliance with clinical and scientific standards. The organization utilized its dermatology-focused proficiency, specialized investigator network, and integrated data management capabilities to support precise data collection and efficient trial execution.

In March 2024, eMed Inc., a United States-based healthcare technology company, acquired Science 37 Holdings, Inc. for an undisclosed sum. With this acquisition, eMed Inc. seeks to broaden its digital clinical trial capabilities, improve patient access to decentralized trials, speed up clinical research timelines, and reinforce its technological infrastructure to support a wider array of therapeutic studies on a global scale. Science 37 Holdings Inc. is a United States-based healthcare technology company that focuses on delivering clinical trial services for allergy-related conditions.

Major companies operating in the allergy clinical trial services market are Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Stallergenes Greer International AG, Torii Pharmaceutical Co. Ltd., ALK‑Abelló A/S, Allergopharma GmbH & Co. KG, Circassia Group plc, Inmunotek S.L., Biomay AG, Laboratorios LETI S.A., Alerje Inc., Inimmune Corporation, Siolta Therapeutics Inc., Allovate Therapeutics Inc., DBV Technologies S.A., Camallergy S.L.

North America was the largest region in the allergy clinical trial services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allergy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergy clinical trial services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergy clinical trial services market includes revenues earned by entities by providing services such as clinical trial design and management, patient recruitment and screening, allergy testing and diagnostics, drug administration and monitoring, data collection and analysis, regulatory compliance support, and biomarker and immunological assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allergy clinical trial services are specialized research programs that evaluate the safety, efficacy, and dosing of new treatments for allergic conditions, including asthma, rhinitis, and food or drug allergies. These services involve carefully designed protocols, patient monitoring, and data collection to generate scientifically robust results that support regulatory approval and clinical use.

The essential service types of allergy clinical trial services include study design and protocol development, site management and patient recruitment, clinical operations and monitoring, bioanalytical and laboratory services, data management and biostatistics, and regulatory affairs and medical writing. Study design and protocol development refers to planning and structuring clinical trials to ensure scientific validity, regulatory compliance, and patient safety. Trials are conducted across Phase I, Phase II, Phase III, and Phase IV or post-marketing studies for allergic rhinitis, allergic asthma, atopic dermatitis, food allergies, and drug hypersensitivity indications. End users include pharmaceutical companies, biotechnology firms, academic research institutions, and government organizations.

Tariffs on imported laboratory equipment, analytical instruments, and data management software are affecting the allergy clinical trial services market by increasing operational and procurement costs, particularly impacting bioanalytical services, laboratory testing, and clinical operations segments. Regions such as North America, Europe, and Asia-Pacific that rely on imported high-precision equipment are most affected. While tariffs elevate costs, they also encourage domestic manufacturing of lab instruments, promote local service providers, and drive innovation in cost-effective clinical trial solutions, ultimately strengthening regional capabilities.

The allergy clinical trial services market research report is one of a series of new reports that provides allergy clinical trial services market statistics, including allergy clinical trial services industry global market size, regional shares, competitors with a allergy clinical trial services market share, detailed allergy clinical trial services market segments, market trends and opportunities, and any further data you may need to thrive in the allergy clinical trial services industry. This allergy clinical trial services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.